Lublin

• Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting
  2024-517032-22-00 5 2025-06-10 Immune system diseases.
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting
  2024-514499-42-00 5 2025-03-12 Refractory Partial Onset Epilepsy
• A study to assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia Recruiting
  2024-515451-38-00 5 2025-02-27 Primary Immune thrombocytopenia (ITP)
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis Recruiting
  2024-512126-29-00 5 2025-02-25 Generalized Myasthenia Gravis
• A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies. Recruiting
  2024-516869-36-00 1 2025-02-17 Relapsed or refractory B-cell malignancies: chronic lymphocytic leukem
• A study to compare effects and safety of CT-P51 and Keytruda in patients with previously untreated metastatic lung cancer Recruiting
  2024-514048-98-00 5 2025-01-30 Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cance
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with … Recruiting
  2023-510369-92-00 4 2025-01-28 Mixed Dyslipidemia
• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting
  2024-511879-16-00 5 2024-12-12 Prurigo Nodularis
• A randomized, two-period crossover study to demonstrate the comparability of pharmacokinetics of subcutaneous ianalumab between 2mL auto-inj … Recruiting
  2023-508996-35-00 4 2024-11-18 Rheumatoid Arthritis
• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting
  2023-506235-15-00 5 2024-11-07 Limited-Stage Small-Cell Lung Cancer (LS SCLC)
• A Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis Recruiting
  2024-512707-40-00 4 2024-11-07 RELAPSING MULTIPLE SCLEROSIS
• Clinical trial of MDNA11 (investigational drug) administered alone or in combination with pembrolizumab (immune checkpoint inhibitor) in Pat … Recruiting
  2023-507536-21-00 7 2024-10-04 Advanced Solid Tumors
• Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting
  2023-508304-38-00 4 2024-09-10 Ulcerative Colitis (UC)
• A Phase 2 study of DNTH103 in patients with Generalized Myasthenia Gravis Recruiting
  2024-512865-15-00 4 2024-09-03 Generalized Myasthenia Gravis
• A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participant … Recruiting
  2023-505678-14-00 4 2024-08-19 Ulcerative Colitis
• A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a … Recruiting
  2023-509606-30-00 5 2024-07-24 Ulcerative colitis
• Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis Recruiting
  2023-507539-40-00 4 2024-07-19 Myasthenia Gravis
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab on background topical corticosteroids therapy in participants aged 1 … Recruiting
  2023-508099-12-00 5 2024-06-20 Dermatitis atopic
• A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting
  2023-503904-10-00 5 2024-06-07 Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
• Efficacy, safety, tolerability, and pharmacokinetics of risankizumab in pediatric subjects with active juvenile psoriatic arthritis Recruiting
  2023-506026-36-00 5 2024-04-29 Juvenile Psoriatic Arthritis
• A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced … Recruiting
  2023-503221-19-00 4 2024-04-18 Advanced Non-Small Cell Lung Cancer
• Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting
  2023-503523-25-00 4 2024-02-29 Non-small cell lung cancer

Showing 97–120 of 789 trials